Hereditary susceptibility with MDM2 gene single nucleotide polymorphism for glioblastoma: Meta-analysis

Objective To explore the association of MDM2 single nucleotide polymorphism with the risk of glioblastoma. Methods This study has searched a great number of papers using key terms based on PubMed, Google Scholar, CNKI, Baidu Scholar before screening samples. To investigate the interaction between MDM2 SNP309 and glioblastoma risk, was performed a Meta-analysis of the risk estimate on case-control studies from six qualified articles. Results The data we reviewed indicated that variant homozygote and heterozygote for MDM2 SNP309 were associated with an increased risk of glioblastoma by 1.23 on odds radio (OR) (95%CI: 1.05-1.44), P=0.288 by I2 test; was performed variant heterozygote of SNP309 significantly increased the risk of cancer by 1.35 on OR (95%CI: 1.05-1.73). In a stratified analysis by ethnicity, this study certified that a significant increased risk in Caucasian by 1.30 on OR(95%CI: 1.08-1.57), P=0.410 by I2 test. Conclusion The analysis indicate MDM2 SNP309 serves as a susceptibility marker on glioblastoma, which was clarified the different risks in ethnicity, especially in Caucasian with variant heterozygote. Key words: MDM2 SNP309; Glioblastoma; Hereditary susceptibility; Meta-analysis